Zobrazeno 31 - 40
of 648
pro vyhledávání: '"Elizabeth M. Jaffee"'
Autor:
Daniel J. Zabransky, Ludmila Danilova, James M. Leatherman, Tamara Y. Lopez‐Vidal, Jessica Sanchez, Soren Charmsaz, Nicole E. Gross, Sarah Shin, Xuan Yuan, Alexei Hernandez, Hongqui Yang, Stephanie Xavier, Daniel Shu, Ali Saeed, Kabeer Munjal, Zeal Kamdar, Luciane T. Kagohara, Elizabeth M. Jaffee, Mark Yarchoan, Won Jin Ho
Publikováno v:
Hepatology
BACKGROUND AND AIMS: The treatment of hepatocellular carcinoma (HCC) has been transformed by the use of immune checkpoint inhibitors. However, most patients with HCC do not benefit from treatment with immunotherapy. There is an urgent need to underst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb8d8e5bded14d7bc88afdbe64239061
https://europepmc.org/articles/PMC9905363/
https://europepmc.org/articles/PMC9905363/
Data from Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy
Autor:
Robert A. Anders, Franck Housseau, Hao Wang, Drew M. Pardoll, Luis A. Diaz, Dung T. Le, Cynthia L. Sears, Jennifer N. Durham, Elizabeth M. Jaffee, Elizabeth D. Thompson, Laveet K. Aulakh, Bjarne R. Bartlett, Qingfeng Zhu, Teniola Oke, Anas H. Awan, Nicholas Siegel, Brandon Luber, Nicolas J. Llosa
Mismatch-repair deficiency in solid tumors predicts their response to PD-1 blockade. Based on this principle, pembrolizumab is approved as standard of care for patients with unresectable or metastatic microsatellite instability–high (MSI-H) cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26bd97c0a7493fb2d388f0fc44d9d416
https://doi.org/10.1158/2326-6066.c.6549880
https://doi.org/10.1158/2326-6066.c.6549880
Autor:
Robert A. Anders, Janis M. Taube, Howard C. Simons, Elizabeth M. Jaffee, Mark Yarchoan, Timothy M. Pawlik, Nicolas J. Llosa, Maria B. Goggins, Feriyl Bhaijee, Elizabeth L. Engle, Farah Succaria, Qingfeng Zhu, Sepideh Besharati, Andrew J. Layman, Faiz Gani, Amy K. Kim
Fibrolamellar carcinoma (FLC) is a rare type of liver cancer that affects adolescents and young adults. The most effective treatment for FLC is surgical resection, but no standardized systemic therapy exists for patients with recurrent or unresectabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::438aef37051a8fdb5604be0134ca6412
https://doi.org/10.1158/2326-6066.c.6550101.v1
https://doi.org/10.1158/2326-6066.c.6550101.v1
Autor:
Dirk G. Brockstedt, Thomas Müller, Chan Whiting, Aimee Murphy, Elizabeth M. Jaffee, Dung T. Le, Serena Chang, Ed Lemmens, Shih-Yu Chen, Nitya Nair
Cellular biomarkers are independent of treatment in the validation patient cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1bea0c40f1e5ccd8590683db394cbcb
https://doi.org/10.1158/2326-6066.22543290.v1
https://doi.org/10.1158/2326-6066.22543290.v1
Autor:
Robert A. Anders, Janis M. Taube, Howard C. Simons, Elizabeth M. Jaffee, Mark Yarchoan, Timothy M. Pawlik, Nicolas J. Llosa, Maria B. Goggins, Feriyl Bhaijee, Elizabeth L. Engle, Farah Succaria, Qingfeng Zhu, Sepideh Besharati, Andrew J. Layman, Faiz Gani, Amy K. Kim
Supplemental Tables 1-3 and Supplemental Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d9153d62f521b49bf6236e81b2e275
https://doi.org/10.1158/2326-6066.22542954
https://doi.org/10.1158/2326-6066.22542954
Autor:
Evanthia T. Roussos Torres, Elana J. Fertig, Elizabeth M. Jaffee, Luciane T. Kagohara, Daria A. Gaykalova, Roisin M. Connolly, Vered Stearns, Srinivasan Yegnasubramanian, Min Yu, Sathish Kumar Ganesan, Sarah J. Wheelan, Michael Considine, Alyza Skaist, Anuj Gupta, Ajay Vaghasia, Emma Bigelow, Gaurav Sharma, Emily F. Davis-Marcisak, Valerie H. Narumi, Brian J. Christmas, Edgar Gonzalez, Aaron G. Baugh, Sofi Castanon, Julie K. Jang, Christine I. Rafie, Dimitrios N. Sidiropoulos
Supplementary Data from Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08e28169c16cf94af543790c359b314a
https://doi.org/10.1158/2326-6066.22544265.v1
https://doi.org/10.1158/2326-6066.22544265.v1
Autor:
Robert A. Anders, Franck Housseau, Hao Wang, Drew M. Pardoll, Luis A. Diaz, Dung T. Le, Cynthia L. Sears, Jennifer N. Durham, Elizabeth M. Jaffee, Elizabeth D. Thompson, Laveet K. Aulakh, Bjarne R. Bartlett, Qingfeng Zhu, Teniola Oke, Anas H. Awan, Nicholas Siegel, Brandon Luber, Nicolas J. Llosa
Supplementary figures 1-6 and tables 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f5184152cc5bb8bc1915666672decd7
https://doi.org/10.1158/2326-6066.22542334
https://doi.org/10.1158/2326-6066.22542334
Autor:
Mark Yarchoan, Elizabeth M. Jaffee, Gregory B. Lesinski, Nilofer Azad, Skylar Woolman, Kayla Cruz, James Leatherman, Aditya Mohan, Amanda Ruggieri, Lauren Dennison
MEK inhibition (MEKi) is proposed to enhance antitumor immunity but has demonstrated mixed results as an immunomodulatory strategy in human clinical trials. MEKi exerts direct immunomodulatory effects on tumor cells and tumor-infiltrating lymphocytes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59d918c2fb90bbefd33af05d7a26deca
https://doi.org/10.1158/2326-6066.c.6550348
https://doi.org/10.1158/2326-6066.c.6550348
Autor:
Mark Yarchoan, Elizabeth M. Jaffee, Gregory B. Lesinski, Nilofer Azad, Skylar Woolman, Kayla Cruz, James Leatherman, Aditya Mohan, Amanda Ruggieri, Lauren Dennison
Supplementary Figures 1-5 and Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::414819427cd0eb1f288b9a1f024de36b
https://doi.org/10.1158/2326-6066.22543654
https://doi.org/10.1158/2326-6066.22543654
Autor:
Mark Yarchoan, Elizabeth M. Jaffee, Robert Anders, Elana J. Fertig, Daniel A. Laheru, Nilofer S. Azad, Ana De Jesus-Acosta, Teena Vithayathil, Qingfeng Zhu, Won Jin Ho, Ludmila Danilova
Immune-checkpoint therapy has failed to demonstrate meaningful clinical benefit in unselected cases of pancreatic adenocarcinoma (PDAC), but a subset of PDACs are known to upregulate pathways involved in acquired immune suppression. Further delineati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ba04085ea6b1f6c251aad833f7c0b7
https://doi.org/10.1158/2326-6066.c.6549891.v1
https://doi.org/10.1158/2326-6066.c.6549891.v1